




Searching News Database: conjunctivitis
HSMN NewsFeed - 2 Feb 2023
Tezspire(R) Approved for Self-Administration in the U.S. with a New Pre-Filled Pen
Tezspire(R) Approved for Self-Administration in the U.S. with a New Pre-Filled Pen
HSMN NewsFeed - 9 Apr 2019
Bluejay Diagnostics, Inc. Announces CE Mark For Its Allereye(R) Tear Total IgE Test
Bluejay Diagnostics, Inc. Announces CE Mark For Its Allereye(R) Tear Total IgE Test
HSMN NewsFeed - 29 Jan 2019
Aldeyra Therapeutics Expands Retinal Disease Pipeline with Acquisition of Helio Vision
Aldeyra Therapeutics Expands Retinal Disease Pipeline with Acquisition of Helio Vision
HSMN NewsFeed - 10 May 2018
Aldeyra Therapeutics Appoints David McMullin as Senior Vice President, Corporate Development and Strategy
Aldeyra Therapeutics Appoints David McMullin as Senior Vice President, Corporate Development and Strategy
HSMN NewsFeed - 24 Apr 2018
Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 3 Clinical Trial
Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 3 Clinical Trial
HSMN NewsFeed - 6 Dec 2017
Third Respiratory Assay Now FDA Cleared on Hologic's New Panther Fusion(R) System
Third Respiratory Assay Now FDA Cleared on Hologic's New Panther Fusion(R) System
HSMN NewsFeed - 22 May 2017
Bluejay Diagnostics' Board Of Directors Announces Appointment Of Douglas C. Wurth As Chairman
Bluejay Diagnostics' Board Of Directors Announces Appointment Of Douglas C. Wurth As Chairman
HSMN NewsFeed - 2 May 2017
Imprimis Pharmaceuticals and SightLife Surgical Sign Agreement for National Launch of Serum Tears(TM)
Imprimis Pharmaceuticals and SightLife Surgical Sign Agreement for National Launch of Serum Tears(TM)
HSMN NewsFeed - 22 Nov 2013
Tivicay(R) (dolutegravir) receives positive CHMP opinion in Europe for the treatment of HIV
Tivicay(R) (dolutegravir) receives positive CHMP opinion in Europe for the treatment of HIV
HSMN NewsFeed - 13 Sep 2012
NovaBay's NeutroPhase(R) Used in New Therapeutic Technique for Management of Necrotizing Fasciitis
NovaBay's NeutroPhase(R) Used in New Therapeutic Technique for Management of Necrotizing Fasciitis
HSMN NewsFeed - 14 Oct 2011
NovaBay Pharmaceuticals Spotlights NeutroPhase(R) at the Symposium on Advanced Wound Care (SAWC)
NovaBay Pharmaceuticals Spotlights NeutroPhase(R) at the Symposium on Advanced Wound Care (SAWC)
HSMN NewsFeed - 13 Oct 2011
ISTA Pharmaceuticals Announces Statistically Significant Phase 3 Results for PROLENSA(TM)
ISTA Pharmaceuticals Announces Statistically Significant Phase 3 Results for PROLENSA(TM)
HSMN NewsFeed - 4 Oct 2011
NovaBay Pharmaceuticals Names David W. Stroman, Ph.D. as Head of Ophthalmic Drug Development
NovaBay Pharmaceuticals Names David W. Stroman, Ph.D. as Head of Ophthalmic Drug Development
HSMN NewsFeed - 28 Sep 2011
NovaBay Pharmaceuticals Names Russell A. Hoon as Vice President of Its Advanced Wound Care Business Unit
NovaBay Pharmaceuticals Names Russell A. Hoon as Vice President of Its Advanced Wound Care Business Unit
HSMN NewsFeed - 17 Feb 2011
Inspire Announces Corporate Restructuring and Strategic Focus on Eye Care Business
Inspire Announces Corporate Restructuring and Strategic Focus on Eye Care Business
HSMN NewsFeed - 3 Jan 2011
Inspire Announces Results of Second Phase 3 Trial with Denufosol for Cystic Fibrosis
Inspire Announces Results of Second Phase 3 Trial with Denufosol for Cystic Fibrosis
HSMN NewsFeed - 12 Oct 2010
Ocular Therapeutix Completes Proof of Principle Study with Moxifloxacin-Loaded Punctum Plugs
Ocular Therapeutix Completes Proof of Principle Study with Moxifloxacin-Loaded Punctum Plugs
HSMN NewsFeed - 1 Sep 2010
Inspire Names Robert Savel as Senior Vice President and Chief Technical Officer
Inspire Names Robert Savel as Senior Vice President and Chief Technical Officer
HSMN NewsFeed - 13 Apr 2010
Inspire Appoints Andrew Koven as Executive Vice President and Chief Administrative and Legal Officer
Inspire Appoints Andrew Koven as Executive Vice President and Chief Administrative and Legal Officer
HSMN NewsFeed - 27 Nov 2009
STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe
STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe
HSMN NewsFeed - 25 Nov 2009
U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine)
U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine)
HSMN NewsFeed - 3 Mar 2009
Pfizer and Bausch & Lomb to Co-Promote Products for the Treatment of Ophthalmic Conditions
Pfizer and Bausch & Lomb to Co-Promote Products for the Treatment of Ophthalmic Conditions
HSMN NewsFeed - 10 Feb 2009
Dyax and Fovea Sign Development and Commercialization Agreement for DX-88 in Ophthalmic Indications
Dyax and Fovea Sign Development and Commercialization Agreement for DX-88 in Ophthalmic Indications
HSMN NewsFeed - 5 Dec 2008
FDA Advisory Committee Recommends Approval of Bausch & Lomb Besifloxacin Anti-Infective Eye Drop
FDA Advisory Committee Recommends Approval of Bausch & Lomb Besifloxacin Anti-Infective Eye Drop
HSMN NewsFeed - 29 Oct 2008
ImClone Announces ERBITUX(R) Commercial Launch in Canada for Advanced Colorectal Cancer
ImClone Announces ERBITUX(R) Commercial Launch in Canada for Advanced Colorectal Cancer
HSMN NewsFeed - 6 Jun 2008
Inspire Announces Achievement of Primary Endpoint in Phase 3 Trial with Denufosol for Cystic Fibrosis
Inspire Announces Achievement of Primary Endpoint in Phase 3 Trial with Denufosol for Cystic Fibrosis
HSMN NewsFeed - 16 Apr 2008
Akorn, Inc. Announces FDA Approval of Ofloxacin Ophthalmic Solution USP, 0.3%
Akorn, Inc. Announces FDA Approval of Ofloxacin Ophthalmic Solution USP, 0.3%
HSMN NewsFeed - 10 Mar 2008
Alcon Announces Leadership Change to Research and Development Organization
Alcon Announces Leadership Change to Research and Development Organization
HSMN NewsFeed - 30 Jan 2008
Lux Granted Fast Track Designation for LX201 for Corneal Transplant Rejection
Lux Granted Fast Track Designation for LX201 for Corneal Transplant Rejection
HSMN NewsFeed - 13 Aug 2007
Inspire Pharmaceuticals Launches AzaSite(TM) in the United States for Ocular Infections
Inspire Pharmaceuticals Launches AzaSite(TM) in the United States for Ocular Infections
HSMN NewsFeed - 20 Jul 2007
Meda Enters the US Market Through the Strategic Acquisition of MedPointe Inc
Meda Enters the US Market Through the Strategic Acquisition of MedPointe Inc
HSMN NewsFeed - 7 Jun 2007
Inspire Adds Stephen D. Celestini as Senior Vice President and Chief Compliance Officer
Inspire Adds Stephen D. Celestini as Senior Vice President and Chief Compliance Officer
HSMN NewsFeed - 4 Jun 2007
YM BioSciences Cleared to Initiate Clinical trial of Nimotuzumab in Colorectal Cancer
YM BioSciences Cleared to Initiate Clinical trial of Nimotuzumab in Colorectal Cancer
HSMN NewsFeed - 30 Apr 2007
InSite Vision Announces FDA Approval for AzaSite(TM) Approval Triggers $19 Million Milestone Payment
InSite Vision Announces FDA Approval for AzaSite(TM) Approval Triggers $19 Million Milestone Payment
HSMN NewsFeed - 20 Oct 2006
FDA Approves Prescription Zaditor(R) for Over-The-Counter Relief From Itchy Eyes
FDA Approves Prescription Zaditor(R) for Over-The-Counter Relief From Itchy Eyes
Additional items found! 41

Members Archive contains
41 additional stories matching:
conjunctivitis
(Password required)
conjunctivitis
(Password required)